$2950 | Single User
$5900 | Site License
$8850 | Enterprise License

Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Insights to 2025
[Report Updated: 31-07-2017]

Published by Delve Insight: 31 Jul 2017 | 116359 | In Stock
Related Topics: Renal Cell Carcinoma

Introduction

DelveInsight’s “Metastatic Renal Cell Carcinoma (mRCC) -Epidemiology Forecast, 2025” provides an overview of the epidemiology trends of Metastatic Renal Cell Carcinoma (mRCC) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Metastatic Renal Cell Carcinoma (mRCC). The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Metastatic Renal Cell Carcinoma (mRCC). The report contains the targeted patient populations and the forecast methodology.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by DelveInsight team of industry experts.

Key Coverage and Benefits

• The Report includes the prevalent population and how will it change over the next eight years.

• Coverage of key Metastatic Renal Cell Carcinoma (mRCC) sub-populations and its prevalent or incident cases

• Prevalent or incident cases segmented by age and sex.

• The key differences in epidemiology patterns across the seven market segments.

Reasons to buy

• Developing business strategies by understanding the trends shaping and driving the global Metastatic Renal Cell Carcinoma (mRCC) market.

• Identifying prevalent patient populations as well as risk factors in the global Metastatic Renal Cell Carcinoma (mRCC) market will help to improve product design, pricing, and launch plans.

• Organize sales and marketing efforts by identifying the best opportunities for Metastatic Renal Cell Carcinoma (mRCC) therapeutics in each of the markets covered.

Table of Contents
for Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Insights to 2025 [Report Updated: 31-07-2017]

  • 1. Report Introduction

    2. Snapshot of Total Prevalent or Incident cases by 7 MM

    3. Executive Summary

    • Key Findings

    4. Metastatic Renal Cell Carcinoma (mRCC) Overview

    • Metastatic Renal Cell Carcinoma (mRCC) Definition

    • Pathophysiology

    • Symptoms

    • Etiology

    5. Risk Factors Associated with Metastatic Renal Cell Carcinoma (mRCC)

    6. Disease Burden & Unmet Need in the Market

    7. Epidemiology and Patient Populations

    • Key Findings

    • Key Sources used and Forecast Methodology

    • Prevalent Cases and Incident Cases-2015-2025

    • Prevalent & Incident Cases by Category-2015-2025

    • Age-Specific Prevalent/ Incident Cases of Metastatic Renal Cell Carcinoma (mRCC)

    • Sex-Specific Prevalent/Incident Cases of Metastatic Renal Cell Carcinoma (mRCC)

    • Disease Type Specific Prevalent/Incident Cases of Metastatic Renal Cell Carcinoma (mRCC)

    8.Prevalent & Incident Cases by 7 MM-2015-2025

    • Metastatic Renal Cell Carcinoma (mRCC) Epidemiology of United States-2025

    • Metastatic Renal Cell Carcinoma (mRCC) Epidemiology of United Kingdom-2025

    • Metastatic Renal Cell Carcinoma (mRCC) Epidemiology of Germany-2025

    • Metastatic Renal Cell Carcinoma (mRCC) Epidemiology of France-2025

    • Metastatic Renal Cell Carcinoma (mRCC) Epidemiology of Spain-2025

    • Metastatic Renal Cell Carcinoma (mRCC) Epidemiology of Italy-2025

    • Metastatic Renal Cell Carcinoma (mRCC) Epidemiology of Japan-2025

    9. Key Takeaways

    10. Appendix

    11.Report Methodology

    12. Consulting Services

    13. Disclaimer

    14. About Us

List Of Tables
in Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Insights to 2025 [Report Updated: 31-07-2017]

Table 1: Clinical subtypes of Indication

Table 2: Risk Factors

Table 3: Prevalence cases (%) Region wise

Table 4: Sources used for forecasting the data

Table 5: Metastatic Renal Cell Carcinoma (mRCC) Global Epidemiology, (2015-2025)

Table 6: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) (Ages =XX Years), US (2015-2025)

Table 7: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) By Sex (Males & Females), US (2015-2025)

Table 8: Prevalent Cases By Metastatic Renal Cell Carcinoma (mRCC) Sub-population, US (2015-2025)

Table 9: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) (Ages =XX Years), United Kingdom (2015-2025)

Table 10: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) By Sex (Males & Females), United Kingdom (2015-2025)

Table 11: Prevalent Cases By Metastatic Renal Cell Carcinoma (mRCC) Sub-population, United Kingdom (2015-2025)

Table 12: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) (Ages =XX Years), Germany (2015-2025)

Table 13: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) By Sex (Males & Females), Germany (2015-2025)

Table 14: Prevalent Cases By Metastatic Renal Cell Carcinoma (mRCC) Sub-population, Germany (2015-2025)

Table 15: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) (Ages =XX Years), France (2015-2025)

Table 16: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) By Sex (Males & Females), France (2015-2025)

Table 17: Prevalent Cases By Metastatic Renal Cell Carcinoma (mRCC) Sub-population, France (2015-2025)

Table 18: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) (Ages =XX Years), Italy (2015-2025)

Table 19: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) By Sex (Males & Females), Italy (2015-2025)

Table 20: Prevalent Cases By Metastatic Renal Cell Carcinoma (mRCC) Sub-population, Italy (2015-2025)

Table 21: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) (Ages =XX Years), Spain (2015-2025)

Table 22: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) By Sex (Males & Females), Spain (2015-2025)

Table 23: Prevalent Cases By Metastatic Renal Cell Carcinoma (mRCC) Sub-population, Spain (2015-2025)

Table 24: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) (Ages =XX Years), Japan (2015-2025)

Table 25: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) By Sex (Males & Females), Japan (2015-2025)

Table 26: Prevalent Cases By Metastatic Renal Cell Carcinoma (mRCC) Sub-population, Japan (2015-2025)

List Of Figures, Charts and Diagrams
in Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Insights to 2025 [Report Updated: 31-07-2017]

Figure 1: Prevalence cases (%) Region wise

Figure 2: Sources used for forecasting the data

Figure 3: Metastatic Renal Cell Carcinoma (mRCC) Global Epidemiology, (2015-2025)

Figure 4: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) (Ages =XX Years), US (2015-2025)

Figure 5: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) By Sex (Males & Females), US (2015-2025)

Figure 6: Prevalent Cases By Metastatic Renal Cell Carcinoma (mRCC) Sub-population,US (2015-2025)

Figure 7: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) (Ages =XX Years), United Kingdom (2015-2025)

Figure 8: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) By Sex (Males & Females), United Kingdom (2015-2025)

Figure 9: Prevalent Cases By Metastatic Renal Cell Carcinoma (mRCC) Sub-population,United Kingdom (2015-2025)

Figure 10: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) (Ages =XX Years), Germany (2015-2025)

Figure 11: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) By Sex (Males & Females), Germany (2015-2025)

Figure 12: Prevalent Cases By Metastatic Renal Cell Carcinoma (mRCC) Sub-population,Germany (2015-2025)

Figure 13: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) (Ages =XX Years), France (2015-2025)

Figure 14: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) By Sex (Males & Females), France (2015-2025)

Figure 15: Prevalent Cases By Metastatic Renal Cell Carcinoma (mRCC) Sub-population,France (2015-2025)

Figure 16: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) (Ages =XX Years), Italy (2015-2025)

Figure 17: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) By Sex (Males & Females), Italy (2015-2025)

Figure 18: Prevalent Cases By Metastatic Renal Cell Carcinoma (mRCC) Sub-population,Italy (2015-2025)

Figure 19: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) (Ages =XX Years), Spain (2015-2025)

Figure 20: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) By Sex (Males & Females), Spain (2015-2025)

Figure 21: Prevalent Cases By Metastatic Renal Cell Carcinoma (mRCC) Sub-population,Spain (2015-2025)

Figure 22: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) (Ages =XX Years), Japan (2015-2025)

Figure 23: Prevalent Cases of Metastatic Renal Cell Carcinoma (mRCC) By Sex (Males & Females), Japan (2015-2025)

Figure 24: Prevalent Cases By Metastatic Renal Cell Carcinoma (mRCC) Sub-population,Japan (2015-2025)

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

116359 | DIEI0143

Number of Pages

40

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016SummaryGlobalData's...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
13 Jul 2014 by FirstWord Pharma USD $695 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Insights to 2025 [Report Updated: 31-07-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)